A bipartite butyrate-responsive element in the human calretinin (CALB2) promoter acts as a repressor in colon carcinoma cells but not in mesothelioma cells

Journal of Cellular Biochemistry

Volumn 109, Issue 3, 2010, Pages 519-531

  Häner, Katrin ^a   Henzi, Thomas ^a   Pfefferli, Martine ^a   Künzli, Esther ^a   Salicio, Valerie ^a   Schwaller, Beat ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Butyrate; Calcium binding protein; Calretinin; Colon cancer; Differentiation; Ef hand

Indexed keywords

BUTYRIC ACID; CALRETININ; REPRESSOR PROTEIN;

ACETYLATION; ARTICLE; CALB2 GENE; CANCER CELL CULTURE; COLON CARCINOMA; COLON MUCOSA; COMPARATIVE STUDY; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TATA BOX;

BASE SEQUENCE; BUTYRATES; CACO-2 CELLS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA PRIMERS; HT29 CELLS; HUMANS; MESOTHELIOMA; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; TATA BOX;

EID: 74949134449     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22429     Document Type: Article

References (52)

1. Allen WL, Coyle VM, Johnston PG. 2006. Predicting the outcome of chemotherapy for colorectal cancer. Curr Opin Pharmacol 6:332-336.
2. Aung CS, Kruger WA, Poronnik P, Roberts-Thomson SJ, Monteith GR. 2007. Plasma membrane Ca2+-ATPase expression during colon cancer cell line differentiation. Biochem Biophys Res Commun 355:932-936.
3. Bach Knudsen KE, Serena A, Canibe N, Juntunen KS. 2003. New insight into butyrate metabolism. Proc Nutr Soc 62:81-86.
4. Baimbridge KG, Celio MR, Rogers JH. 1992. Calcium-binding proteins in the nervous system. Trends Neurosci 15:303-308.
5. Bearzatto B, Servais L, Roussel C, Gall D, Baba-Aissa F, Schurmans S, de Kerchove d'Exaerde A, Cheron G, Schiffmann SN. 2006. Targeted calretinin expression in granule cells of calretinin-null mice restores normal cerebellar functions. FASEB J 20:380-382.
6. Billing-Marczak K, Kuznicki J. 1999. Calretinin-sensor or buffer-function still unclear. Pol J Pharmacol 51:173-178.
7. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C, Johnston PG. 2006. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66:2765-2777.
8. Bras-Goncalves RA, Pocard M, Formento JL, Poirson-Bichat F, De Pinieux G, Pandrea I, Arvelo F, Ronco G, Villa P, Coquelle A, Milano G, Lesuffleur T, Dutrillaux B, Poupon MF. 2001. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 120:874-888.
9. Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA. 2007. Functional genomic analysis reveals crosstalk between peroxisome proliferator-activated receptor gamma (PPARgamma) and calcium signaling in human colorectal cancer cells. J Biol Chem 282:23387-23401.
10. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. 2001. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25:562-568.
11. Cargnello R, Celio MR, Schwaller B, Gotzos V. 1996. Change of calretinin expression in the human colon adenocarcinoma cell line HT29 after differentiation. Biochim Biophys Acta 1313:201-208.
12. Carrel S, Sordat B, Merenda C. 1976. Establishment of a cell line (Co115) from a human colon carcinoma transplanted into nude mice. Cancer Res 36:3978-3984.
13. Chen ZY, Rex S, Tseng CC. 2004. Kruppel-like factor 4 is transactivated by butyrate in colon cancer cells. J Nutr 134:792-798.
14. Cordel S, Heymann MF, Boisteau O, Oliver L, Le Pendu J, Gregoire M, Meflah K. 1997. 5-Fluorouracil-resistant colonic tumors are highly responsive to sodium butyrate/interleukin-2 biotherapy in rats. Int J Cancer 73:924-928.
15. Daly K, Cuff MA, Fung F, Shirazi-Beechey SP. 2005. The importance of colonic butyrate transport to the regulation of genes associated with colonic tissue homoeostasis. Biochem Soc Trans 33:733-735.
16. Doglioni C, Tos APD, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, Viale G. 1996. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surgical Pathol 20:1037-1046.
17. Faas GC, Schwaller B, Vergara JL, Mody I. 2007. Resolving the fast kinetics of cooperative binding: Ca2+ buffering by calretinin. PLoS Biol 5:e311. 10.1371/journal.pbio.0050311.
18. Fukushima A, Aizaki Y, Sakuma K. 2009. Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells. J Nutr 139:20-25.
19. Gander JC, Gotzos V, Fellay B, Schwaller B. 1996. Inhibition of the proliferative cycle and apoptotic events in WiDr cells after down-regulation of the calcium-binding protein calretinin using antisense oligodeoxynucleotides. Exp Cell Res 225:399-410.
20. Gill RK, Christakos S. 1993. Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrateinducible responses. Proc Natl Acad Sci USA 90:2984-2988.
21. Gotzos V, Schwaller B, Hetzel N, Bustos-Castillo M, Celio MR. 1992. Expression of the calcium binding protein calretinin in WiDr cells and its correlation to their cell cycle. Exp Cell Res 202:292-302.
22. Gotzos V, Schwaller B, Gander JC, Bustos-Castillo M, Celio MR. 1996a. Heterogeneity of expression of the calcium-binding protein calretinin in human colonic cancer cell lines. Anticancer Res 16:3491-3498.
23. Gotzos V, Vogt P, Celio MR. 1996b. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 192:137-147.
24. Gotzos V, Wintergerst ES, Musy JP, Spichtin HP, Genton CY. 1999. Selective distribution of calretinin in adenocarcinomas of the human colon and adjacent tissues. Am J Surg Pathol 23:701-711.
25. Haas MJ, Cosgrove DE, Xiong W, Cox GS. 1999. Sodium butyrate-mediated induction of the glycoprotein hormone alpha-subunit gene: Requirement for continued protein synthesis, identification of a butyrate-responsive element, and inhibition of promoter activation by 2-deoxyglucose. J Cell Biochem 74:242-263.
26. Henzi T, Blum WV, Pfefferli M, Kawecki TJ, Salicio V, Schwaller B. 2009. SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 174:2324-2336.
27. Iacomino G, Tecce MF, Grimaldi C, Tosto M, Russo GL. 2001. Transcriptional response of a human colon adenocarcinoma cell line to sodium butyrate. Biochem Biophys Res Commun 285:1280-1289.
28. Lallemand F, Courilleau D, Sabbah M, Redeuilh G, Mester J. 1996. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem Biophys Res Commun 229:163-169.
29. Lamprecht SA, Lipkin M. 2003. Chemoprevention of colon cancer by calcium, vitamin D and folate: Molecular mechanisms. Nat Rev Cancer 3: 601-614.
30. Lesuffleur T, Kornowski A, Augeron C, Dussaulx E, Barbat A, Laboisse C, Zweibaum A. 1991. Increased growth adaptability to 5-fluorouracil and methotrexate of HT-29 sub-populations selected for their commitment to differentiation. Int J Cancer 49:731-737.
31. Longley DB, Allen WL, Johnston PG. 2006. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 1766:184-196.
32. Mariadason JM, Corner GA, Augenlicht LH. 2000. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60:4561-4572.
33. Marilley D, Vonlanthen S, Gioria A, Schwaller B. 2001. Calretinin and calretinin-22k increase resistance towards sodium butyrate-induced differentiation in CaCo-2 colon adenocarcinoma cells. Exp Cell Res 268:93-103.
34. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. 2007. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 223:277-287.
35. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T. 1997. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272:22199-22206.
36. Racay P, Gregory P, Schwaller B. 2006. Parvalbumin deficiency in fast-twitch muscles leads to increased 'slow-twitch type' mitochondria, but does not affect the expression of fiber specific proteins. FEBS J 273:96-108.
37. Rao J, Otto WR. 1992. Fluorimetric DNA assay for cell growth estimation. Anal Biochem 207:186-192.
38. Reddy BS. 2000. The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev 9:239-247.
39. Roediger WE. 1982. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 83:424-429.
40. Saydan N, Salicio V, Cappelli-Gotzos B, Gotzos V. 2001. Expression of calretinin in human mesothelioma cell lines and cell cycle analysis by flow cytometry. Anticancer Res 21:181-188.
41. Schmitter D, Lauber B, Fagg B, Stahel RA. 1992. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin-6 production as a common feature. Int J Cancer 51:296-301.
42. Schwab M, Reynders V, Ulrich S, Zahn N, Stein J, Schroder O. 2006. PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 11:1801-1811.
43. Schwaller B, Herrmann B. 1997. Regulated redistribution of calretinins in WiDr cells. Cell Death Differ 4:325-333.
44. Schwaller B, Buchwald P, Blumcke I, Celio MR, Hunziker W. 1993. Characterization of a polyclonal antiserum against the purified human recombinant calcium binding protein calretinin. Cell Calcium 14:639-648.
45. Schwaller B, Celio MR, Hunziker W. 1995. Alternative splicing of calretinin mRNA leads to different forms of calretinin. Eur J Biochem 230:424-430.
46. Siavoshian S, Blottiere HM, Le Foll E, Kaeffer B, Cherbut C, Galmiche JP. 1997. Comparison of the effect of different short chain fatty acids on the growth and differentiation of human colonic carcinoma cell lines in vitro. Cell Biol Int 21:281-287.
47. Stokrova J, Sloncova E, Sovova V, Kucerova D, Zila V, Tureckova J, Vojtechova M, Korb J, Tuhackova Z. 2006. Characterization of four clones derived from human adenocarcinoma cell line, HT29, and analysis of their response to sodium butyrate. Int J Oncol 28:559-565.
48. Tabuchi Y, Arai Y, Kondo T, Takeguchi N, Asano S. 2002. Identification of genes responsive to sodium butyrate in colonic epithelial cells. Biochem Biophys Res Commun 293:1287-1294.
49. Tabuchi Y, Takasaki I, Doi T, Ishii Y, Sakai H, Kondo T. 2006. Genetic networks responsive to sodium butyrate in colonic epithelial cells. FEBS Lett 580:3035-3041.
50. Tran CP, Familari M, Parker LM, Whitehead RH, Giraud AS. 1998. Shortchain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. Am J Physiol 275:G85-G94.
51. Tsubaki J, Hwa V, Twigg SM, Rosenfeld RG. 2002. Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells. Endocrinology 143:1778-1788.
52. Vonlanthen S, Kawecki TJ, Betticher DC, Pfefferli M, Schwaller B. 2007. A single nucleotide polymorphism (SNP) in intron 9 of the human calretinin gene is a risk factor and is linked to calretinin expression in colon tumors, but not in lung tumors. Anticancer Res 27:4279-4288.